PL3377483T3 - Pochodne n-podstawionego indolu jako modulatory receptora pge2 - Google Patents

Pochodne n-podstawionego indolu jako modulatory receptora pge2

Info

Publication number
PL3377483T3
PL3377483T3 PL16797577T PL16797577T PL3377483T3 PL 3377483 T3 PL3377483 T3 PL 3377483T3 PL 16797577 T PL16797577 T PL 16797577T PL 16797577 T PL16797577 T PL 16797577T PL 3377483 T3 PL3377483 T3 PL 3377483T3
Authority
PL
Poland
Prior art keywords
receptor modulators
indole derivatives
substituted indole
pge2 receptor
pge2
Prior art date
Application number
PL16797577T
Other languages
English (en)
Inventor
Heinz Fretz
Isabelle Lyothier
Julien Pothier
Sylvia Richard-Bildstein
Thierry Sifferlen
Lorenza WYDER PETERS
Davide Pozzi
Olivier Corminboeuf
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of PL3377483T3 publication Critical patent/PL3377483T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16797577T 2015-11-20 2016-11-17 Pochodne n-podstawionego indolu jako modulatory receptora pge2 PL3377483T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2015077269 2015-11-20
PCT/EP2016/078028 WO2017085198A1 (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators
EP16797577.0A EP3377483B9 (en) 2015-11-20 2016-11-17 N-substituted indole derivatives as pge2 receptor modulators

Publications (1)

Publication Number Publication Date
PL3377483T3 true PL3377483T3 (pl) 2022-01-31

Family

ID=57326428

Family Applications (2)

Application Number Title Priority Date Filing Date
PL21186831.0T PL3928836T3 (pl) 2015-11-20 2016-11-17 Pochodne n-podstawionego indolu jako modulatory receptora pge2
PL16797577T PL3377483T3 (pl) 2015-11-20 2016-11-17 Pochodne n-podstawionego indolu jako modulatory receptora pge2

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL21186831.0T PL3928836T3 (pl) 2015-11-20 2016-11-17 Pochodne n-podstawionego indolu jako modulatory receptora pge2

Country Status (34)

Country Link
US (2) US11241431B2 (pl)
EP (2) EP3377483B9 (pl)
JP (2) JP2018534328A (pl)
KR (1) KR102352022B1 (pl)
CN (1) CN108349949B (pl)
AU (1) AU2016358242B2 (pl)
BR (1) BR112018010291B1 (pl)
CA (1) CA3002610C (pl)
CL (1) CL2018001325A1 (pl)
CO (1) CO2018005715A2 (pl)
CR (1) CR20180323A (pl)
CY (1) CY1124913T1 (pl)
DK (2) DK3928836T3 (pl)
EA (1) EA037953B1 (pl)
ES (2) ES2994636T3 (pl)
FI (1) FI3928836T3 (pl)
HR (2) HRP20241521T1 (pl)
HU (2) HUE056679T2 (pl)
IL (1) IL259424B (pl)
LT (2) LT3377483T (pl)
MA (2) MA43251B1 (pl)
MX (1) MX375978B (pl)
MY (1) MY195888A (pl)
PE (1) PE20181304A1 (pl)
PH (1) PH12018501077B1 (pl)
PL (2) PL3928836T3 (pl)
PT (2) PT3928836T (pl)
RS (2) RS62598B1 (pl)
SA (1) SA518391588B1 (pl)
SG (1) SG11201803627XA (pl)
SI (2) SI3377483T1 (pl)
TW (2) TWI719078B (pl)
UA (1) UA123441C2 (pl)
WO (1) WO2017085198A1 (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018176134A1 (en) 2017-03-27 2018-10-04 HYDRO-QUéBEC Salts for use in electrolyte compositions or as electrode additives
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
CN109678780A (zh) * 2017-10-19 2019-04-26 中国石油化工股份有限公司 一种制备3-烷基吲哚衍生物的方法
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CN111819193A (zh) 2018-01-05 2020-10-23 西奈山伊坎医学院 增加胰腺β细胞增殖的方法、治疗方法以及组合物
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
CA3124353A1 (en) * 2018-12-31 2020-07-09 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3693359A1 (en) * 2019-02-08 2020-08-12 Medibiofarma, S.L. New n-benzyl-2-phenoxybenzamide derivatives as prostaglandin e2 (pge2) receptors modulators
WO2021060281A1 (ja) * 2019-09-24 2021-04-01 Ａｇｃ株式会社 プロスタグランジンｅ２レセプターｅｐ２／ｅｐ４デュアルアンタゴニスト
EP4054719B1 (en) 2019-11-04 2026-02-11 Revolution Medicines, Inc. Ras inhibitors
CR20230165A (es) 2020-09-15 2023-06-02 Revolution Medicines Inc Derivados indólicos como inhibidores de ras en el tratamiento del cáncer
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
WO2022272062A1 (en) 2021-06-24 2022-12-29 Reservoir Neuroscience, Inc. Ep2 antagonist compounds
WO2025229177A1 (en) 2024-05-02 2025-11-06 Idorsia Pharmaceuticals Ltd Crystalline forms of an n-substituted indole derivative

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
JP2003528144A (ja) 2000-03-24 2003-09-24 ファーマジーン ラボラトリーズ リミテッド 頭痛治療のためのプロスタノイドｅｐ４受容体アンタゴニストの使用およびそのアンタゴニストについてのアッセイ
HN2001000224A (es) 2000-10-19 2002-06-13 Pfizer Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos.
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
JP2005532291A (ja) 2002-04-12 2005-10-27 ファイザー株式会社 抗炎症薬および鎮痛薬としてのピラゾール化合物
AU2003216579A1 (en) 2002-04-12 2003-10-27 Pfizer Inc. Imidazole compounds as anti-inflammatory and analgesic agents
US20040023853A1 (en) 2002-05-23 2004-02-05 Peri Krishna G. Antagonistic peptides of prostaglandin E2 receptor subtype EP4
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
EP1661897B1 (en) 2003-08-26 2013-12-04 Teijin Pharma Limited Pyrrolopyrimidinone derivative
RS20060143A (sr) 2003-09-03 2008-06-05 Pfizer Inc., Jedinjenja fenil ili piridil amida kao antagonisti prostaglandina e2
EP1678147B1 (en) 2003-09-15 2012-08-08 Lead Discovery Center GmbH Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
US7326732B2 (en) 2004-02-12 2008-02-05 Pharmagene Laboratories Limited EP2 receptor agonists
JP4054368B2 (ja) 2004-05-04 2008-02-27 ファイザー株式会社 置換メチルアリール又はヘテロアリールアミド化合物
CN1950334A (zh) 2004-05-04 2007-04-18 辉瑞有限公司 邻位取代的芳基或杂芳基酰胺化合物
HN2005000795A (es) * 2004-10-15 2010-08-19 Aventis Pharma Inc Pirimidinas como antagonistas del receptor de prostaglandina d2
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
AR060403A1 (es) 2006-04-12 2008-06-11 Sanofi Aventis Compuestos de amino- pirimidina 2,6- sustituidos -4- monosustituidos como antagonistas del receptor de prostaglandina d2
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
US7705035B2 (en) 2006-06-12 2010-04-27 Merck Frosst Canada Ltd. Indoline amide derivatives as EP4 receptor ligands
US20080280891A1 (en) 2006-06-27 2008-11-13 Locus Pharmaceuticals, Inc. Anti-cancer agents and uses thereof
WO2008008059A1 (en) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Anti-cancer agents ans uses thereof
BRPI0714409A2 (pt) * 2006-07-14 2013-03-12 Novartis Ag derivados de pirimidina como inibidores de alk-5
CA2660133C (en) 2006-08-11 2015-10-27 Merck Frosst Canada Ltd. Thiophenecarboxamide derivatives as ep4 receptor ligands
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
US8158671B2 (en) 2007-02-26 2012-04-17 Merck Canada Inc. Indole and indoline cyclopropyl amide derivatives as EP4 receptor antagonists
MX2009010297A (es) 2007-03-26 2009-10-12 Astellas Pharma Inc Derivado de ornitina.
JP2010522218A (ja) 2007-03-26 2010-07-01 メルク フロスト カナダ リミテツド Ｅｐ４受容体アンタゴニストとしてのナフタレン及びキノリンスルホニル尿素誘導体
EP2014657A1 (de) 2007-06-21 2009-01-14 Bayer Schering Pharma Aktiengesellschaft Diaminopyrimidine als Modulatoren des EP2-Rezeptors
US20110028463A1 (en) 2007-07-03 2011-02-03 Astellas Pharma Inc. Amide compounds
CA2702008A1 (en) 2007-10-12 2009-04-16 Ingenium Pharmaceuticals Gmbh Inhibitors of protein kinases
US8598202B2 (en) 2008-02-19 2013-12-03 Janssen Pharmaceutica Nv Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase
SI2565191T1 (sl) 2008-05-14 2014-12-31 Astellas Pharma Inc. Derivati 4-(indol-7-ilkarbonilaminometil)cikloheksan karboksilne kisline kot EP4 receptorski antagonisti, uporabni za zdravljenje kronične ledvične odpovedi ali diabetične nefropatije
US20130225528A1 (en) 2008-05-21 2013-08-29 Ariad Pharmaceuticals, Inc. Phosphorus Derivatives as Kinase Inhibitors
EP2320906B1 (en) 2008-08-14 2016-02-24 Beta Pharma Canada Inc. Heterocyclic amide derivatives as ep4 receptor antagonists
CN102164942B (zh) 2008-09-19 2017-02-15 生物科技研究有限公司 三萜系化合物及其使用的方法
CN102224154A (zh) 2008-09-25 2011-10-19 默克弗罗斯特加拿大有限公司 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物
US8906914B2 (en) 2009-08-18 2014-12-09 Janssen Pharmaceutica Nv Ethylene diamine modulators of fatty acid hydrolase
EP2504008A1 (en) 2009-11-23 2012-10-03 Lexicon Pharmaceuticals, Inc. Methods and assays for the treatment of irritable bowel syndrome
CN103003264B (zh) 2010-05-21 2014-08-06 切米利亚股份公司 嘧啶衍生物
PH12013500467A1 (en) 2010-09-21 2013-04-29 Eisai R&D Man Co Ltd Pharmaceutical composition
JP5273689B2 (ja) 2010-09-29 2013-08-28 株式会社エヌビィー健康研究所 ヒトプロスタグランジンｅ２受容体ｅｐ４に対する抗体
WO2012066065A1 (en) 2010-11-17 2012-05-24 Novartis Ag Phenyl-heteroaryl amine compounds and their uses
EA201390717A1 (ru) 2010-11-17 2013-10-30 Новартис Аг 3-(аминоарил)пиридиновые соединения
CA2820109C (en) 2010-12-10 2018-01-09 Rottapharm S.P.A. Pyridine amide derivatives as ep4 receptor antagonists
WO2012103071A2 (en) 2011-01-25 2012-08-02 Eisai R&D Management Co., Ltd. Compounds and compositions
CA2830129C (en) 2011-03-24 2016-07-19 Chemilia Ab Novel pyrimidine derivatives
EP2702043A1 (en) 2011-04-29 2014-03-05 Exelixis, Inc. Inhibitors of inducible form of 6-phosphofructose-2-kinase
US9518044B2 (en) 2011-06-20 2016-12-13 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US9181279B2 (en) 2011-07-04 2015-11-10 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor antagonists
EP2554662A1 (en) 2011-08-05 2013-02-06 M Maria Pia Cosma Methods of treatment of retinal degeneration diseases
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
IN2014KN02601A (pl) 2012-04-24 2015-05-08 Vertex Pharma
AR091429A1 (es) 2012-06-29 2015-02-04 Lilly Co Eli Compuestos de fenoxietil piperidina
TWI572597B (zh) 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
EP2711364A1 (en) * 2012-09-21 2014-03-26 Chemilia AB 4-(Indolyl or benzimidazolyl)amino-2-(2-(indol-3-yl)ethyl)aminopyrimidines useful for the treatment of cancer
CA2888338C (en) 2012-11-27 2021-07-20 Thomas Helledays Stiftelse For Medicinsk Forskning Mth1 inhibitors for treatment of cancer
UA115576C2 (uk) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
EP2765128A1 (en) 2013-02-07 2014-08-13 Almirall, S.A. Substituted benzamides with activity towards EP4 receptors
TW201443004A (zh) 2013-02-15 2014-11-16 Lilly Co Eli 苯氧基乙氧基化合物
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫－１ｈ－異喹啉化合物
PT3009426T (pt) 2013-06-12 2018-06-08 Kaken Pharma Co Ltd Derivado de 4-alquinilimidazole e medicamento compreendendo o mesmo como ingrediente ativo
EA029901B1 (ru) 2013-09-04 2018-05-31 Бристол-Майерс Сквибб Компани Соединения для применения в качестве иммуномодуляторов
CU24362B1 (es) 2013-09-06 2018-10-04 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
WO2015044900A1 (en) 2013-09-27 2015-04-02 Aurigene Discovery Technologies Limited Therapeutic immunomodulating compounds
ES2705342T3 (es) 2013-10-17 2019-03-22 Vertex Pharma Co-cristales de (S)-N-metil-8-(1-((2'-metil-[4,5'-bipirimidin]-6-il)amino)propan-2-il)quinolin-4-carboxamida y derivados deuterados de la misma como inhibidores de DNA-PK
WO2015058031A1 (en) 2013-10-17 2015-04-23 Vertex Pharmaceuticals Incorporated Dna-pk inhibitors
EA028921B1 (ru) 2013-12-17 2018-01-31 Эли Лилли Энд Компани Феноксиэтилы
DK3083554T3 (da) 2013-12-17 2019-05-13 Lilly Co Eli Dimethylbenzoesyreforbindelser
TW201607943A (zh) 2013-12-19 2016-03-01 拜耳製藥公司 作為ｅｐ４配體之新穎苯并咪唑衍生物
TW201623277A (zh) 2014-03-26 2016-07-01 安斯泰來製藥股份有限公司 醯胺化合物
US10052332B2 (en) 2014-04-29 2018-08-21 Emory University Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto
US20170182003A1 (en) 2014-05-23 2017-06-29 Eisai R&D Management Co., Ltd. Combination therapies for the treatment of cancer
RU2016151390A (ru) 2014-06-04 2018-07-17 Томас Хелледайс Стифтелсе Фёр Медисинск Форскнинг Ингибиторы мтн1 для лечения воспалительных и аутоиммунных заболеваний
WO2016021742A1 (en) 2014-08-07 2016-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds as ep4 receptor antagonists
TWI739666B (zh) 2015-01-09 2021-09-11 日商小野藥品工業股份有限公司 醫藥組成物
EP3325490B1 (en) 2015-07-23 2019-12-18 Takeda Pharmaceutical Company Limited 1-substituted 1,2,3,4-tetrahydro-1,7-naphthyridin-8-amine derivatives and their use as ep4 receptor antagonists
MX390051B (es) 2015-10-16 2025-03-20 Eisai R&D Man Co Ltd Antagonistas de ep4.
CR20180323A (es) * 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
AU2017295720B2 (en) 2016-07-13 2021-07-22 Vertex Pharmaceuticals Incorporated Methods, compositions and kits for increasing genome editing efficiency
EP3625223B1 (en) 2017-05-18 2021-08-11 Idorsia Pharmaceuticals Ltd Pyrimidine derivatives
AR111941A1 (es) 2017-05-18 2019-09-04 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2
US20200069686A1 (en) 2017-05-18 2020-03-05 Idorsia Pharmaceuticals Ltd N-substituted indole derivatives
JP7093791B2 (ja) 2017-05-18 2022-06-30 イドーシア ファーマシューティカルズ リミテッド Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体
MX388257B (es) 2017-05-18 2025-03-19 Idorsia Pharmaceuticals Ltd Derivados de pirimidina como moduladores del receptor de pge2.

Also Published As

Publication number Publication date
JP2021107417A (ja) 2021-07-29
EP3377483A1 (en) 2018-09-26
MA43251B1 (fr) 2021-11-30
IL259424B (en) 2020-11-30
CN108349949A (zh) 2018-07-31
DK3377483T3 (da) 2021-12-06
RS66179B1 (sr) 2024-12-31
LT3377483T (lt) 2021-11-10
UA123441C2 (uk) 2021-04-07
TW202120497A (zh) 2021-06-01
HRP20241521T1 (hr) 2025-01-03
CY1124913T1 (el) 2023-01-05
JP2018534328A (ja) 2018-11-22
SI3928836T1 (sl) 2025-03-31
KR20180081810A (ko) 2018-07-17
RS62598B1 (sr) 2021-12-31
MA55046A (fr) 2021-12-29
TW201726661A (zh) 2017-08-01
HRP20211678T1 (hr) 2022-03-04
AU2016358242B2 (en) 2021-03-11
PL3928836T3 (pl) 2025-01-07
AU2016358242A1 (en) 2018-07-05
EP3377483B1 (en) 2021-09-01
BR112018010291B1 (pt) 2023-12-26
CN108349949B (zh) 2020-11-17
MX2018005268A (es) 2018-11-29
KR102352022B1 (ko) 2022-01-14
WO2017085198A1 (en) 2017-05-26
SA518391588B1 (ar) 2021-03-17
TWI754397B (zh) 2022-02-01
TWI719078B (zh) 2021-02-21
PH12018501077A1 (en) 2019-01-28
MY195888A (en) 2023-02-27
DK3928836T3 (da) 2024-10-14
MA55046B1 (fr) 2024-10-31
CA3002610A1 (en) 2017-05-26
EP3377483B9 (en) 2022-08-03
FI3928836T3 (fi) 2024-11-08
CR20180323A (es) 2018-08-06
ES2897954T3 (es) 2022-03-03
CA3002610C (en) 2022-03-15
JP7228618B2 (ja) 2023-02-24
US20220175775A1 (en) 2022-06-09
US20200289507A1 (en) 2020-09-17
EP3928836A1 (en) 2021-12-29
EA201891179A1 (ru) 2018-11-30
HUE069520T2 (hu) 2025-03-28
CO2018005715A2 (es) 2018-07-10
PE20181304A1 (es) 2018-08-09
HUE056679T2 (hu) 2022-02-28
SG11201803627XA (en) 2018-06-28
MA43251A (fr) 2021-04-28
MX375978B (es) 2025-03-07
EP3928836B1 (en) 2024-09-18
ES2994636T3 (en) 2025-01-28
LT3928836T (lt) 2024-12-27
CL2018001325A1 (es) 2018-08-10
IL259424A (en) 2018-07-31
SI3377483T1 (sl) 2022-01-31
BR112018010291A2 (pt) 2018-11-06
PT3928836T (pt) 2024-11-29
US12011444B2 (en) 2024-06-18
PH12018501077B1 (en) 2019-01-28
US11241431B2 (en) 2022-02-08
EA037953B1 (ru) 2021-06-11
PT3377483T (pt) 2021-11-22

Similar Documents

Publication Publication Date Title
IL259424B (en) Nitrogen-substituted indole derivatives as pge2 receptor modulators
IL270620A (en) Pyrimidine history as PGE2 receptor modulators
PL3625222T3 (pl) Pochodne fenylu jako modulatory receptora pge2
SI3625224T1 (sl) N-substituirani indolni derivati
IL249267A0 (en) Materials containing carbonitrile and their use for selective modulation of the androgen receptor
ZA201705486B (en) Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
DK3145916T3 (da) Imidazolderivater som formylpeptidreceptormodulatorer
IL257869A (en) Fluoroindole derivatives as positive allosteric modulators for muscarinic receptor am.1
IL254711A0 (en) History of Indole
HK1260563A1 (en) N-substituted indole derivatives as pge2 receptor modulators
ZA201908398B (en) N-substituted indole derivatives